Comments 1 - 1 of 1 Search these comments
The origins of RSV
Most people don’t realize that RSV made the leap from chimpanzees to humans because of shoddy research to develop a polio vaccine. From Children’s Health Defense:
What we know from the research on RSV:
• Chimpanzee Coryza Virus (CCV) was first identified in 1955 in a group of chimps used for polio research at Walter Reed Army Research Institute in Silver Springs, Maryland.
• The caretaker for the apes also developed CCV in early 1956, and the virus spread from the caretaker to several of his bunk mates at the institute located in Silver Springs.
• One year later, in 1957, a new virus was found in infants in Baltimore. That virus, identical to CCV, was renamed Respiratory Syncytial Virus (RSV).
• Five years later, RSV virus was responsible for the majority of severe respiratory infections in infants and young children across the globe.
In short, the introduction of RSV from apes used for the development of polio vaccine in the 1950s resulted in the creation of a new respiratory disease that the World Health Organization (WHO) now estimates results in more than 3 million hospitalizations and nearly 60,000 deaths in children under 5 years of age every year.
So the RSV shot that they are selling via every TV channel in America is in response to the RSV virus they created.
Over 57,000 hospitalizations, 500,000 emergency department visits and 1.5 million outpatient clinic visits among children <5 years of age are attributed to respiratory syncytial virus (RSV) infections each year in the United States. RSV-associated deaths among children <5 years of age are thought to be uncommon, estimated at 100-500 per year. Among US adults, an estimated 177,000 hospitalizations and 14,000 deaths associated with RSV infections occur annually. However, these are likely underestimates of RSV-associated deaths. In recent years, laboratory testing for RSV has increased in availability and practice. A more accurate assessment of RSV-associated deaths is important for establishing a baseline level of mortality ahead of the potential licensures of vaccines, immunoprophylaxis products, and anti-viral therapies. Additionally, a better understanding about who is at risk of RSV-associated deaths may help identify populations to target for interventions.
Clinical Criteria
A respiratory syncytial virus (RSV)-associated death is defined for surveillance purposes as a death resulting from a clinically compatible illness that was confirmed to be RSV by an appropriate laboratory or rapid diagnostic test. There should be no period of complete recovery between the illness and death.
A death should not be categorized as an RSV-associated death if:
There is no laboratory confirmation of RSV infection.
The RSV illness is followed by full recovery to baseline health status prior to death.
After review and consultation, it is determined that RSV infection did not contribute to death.
Laboratory Criteria for Diagnosis
Confirmatory laboratory evidence:
Laboratory testing for respiratory syncytial virus infection may be done on pre- or post-mortem clinical specimens, and include identification of RSV (A, B, or unspecified) infection by a positive result by at least one of the following:
Isolation of respiratory syncytial virus by tissue cell culture
Detection of respiratory syncytial virus nucleic acid by reverse-transcriptase polymerase chain reaction (RT-PCR) or other nucleic acid detection assay
Detection of respiratory syncytial virus antigen by immunofluorescent antibody staining (direct or indirect)
Detection of respiratory syncytial virus antigens by immunochromatographic or similar rapid laboratory test
Detection of respiratory syncytial virus antigens from autopsy specimens by immunohistochemical (IHC) staining
Case Classification
Confirmed
A death meeting the clinical and laboratory criteria.
https://wwwn.cdc.gov/nndss/conditions/respiratory-syncytial-virus-associated-mortality/case-definition/2019/